MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 Page 1

MacroGenics will host an investor call on Monday, September 16, 2024 at 8:00 a.m. ET to discuss key data presented at ESMO

ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapies for the treatment of cancer, today announced a poster presentation detailing Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024 in Barcelona, ​​Spain.

The following poster will be available on Sunday, September 15, 2024: